SubsidieMeestersFighting Large-Scale Untreated Infectious Diseases with Innovative Treatments
Meletios is developing a broad-spectrum oral antiviral that targets cell mechanisms to treat acute viral infections, starting with COVID-19, while also managing immune responses.
Projectdetails
Introduction
Founded in 2020, Meletios is developing innovative antiviral strategies to treat existing and emerging acute viral infections. Among those, our lead program, presented at the EIC Accelerator, is an oral Host-Directed Agent targeting cell mechanisms hijacked by viruses.
Mechanism of Action
By acting on cell membrane’s fluidity, our antiviral strongly limits cell internalization and intracellular trafficking of viruses. This approach could be effective against broad virus families, conferring our molecule with an advantageous broad-spectrum effect, a key strategy to boost our capacities to ward off outbreaks.
Immunomodulatory Effects
Moreover, our agent has immunomodulatory effects enabling us to efficiently manage viral diseases by preventing excessive immune system reactions.
Development Process
We will perform an accelerated development process as our molecule has already proved its safety in humans.
Targeted Diseases
COVID-19 will be the first demonstrator of our molecule’s efficacy, before targeting diseases induced by other coronaviruses, influenza, and flaviviruses.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 4.582.237 |
Tijdlijn
| Startdatum | 1-1-2023 |
| Einddatum | 31-12-2024 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- MELETIOS THERAPEUTICSpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
The first broad-spectrum treatment against pandemic-prone flaviviral infections: Dengue, West-Nile and ZikaATLAS aims to develop the first broad-spectrum antiviral for flavivirus infections, conducting Phase I and IIa trials for dengue to attract pharmaceutical partnerships for commercialization. | EIC Accelerator | € 2.499.999 | 2023 | Details |
The first broad-spectrum treatment against pandemic-prone flaviviral infections: Dengue, West-Nile and Zika
ATLAS aims to develop the first broad-spectrum antiviral for flavivirus infections, conducting Phase I and IIa trials for dengue to attract pharmaceutical partnerships for commercialization.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Virus Inhibition by siRNA Optimized by NMRThis project aims to develop a novel class of siRNA molecules targeting SARS-CoV-2 variants using structural biology, with potential applications for other pathogenic viruses. | ERC Proof of... | € 150.000 | 2022 | Details |
Molecular dissection of viral genomes for future antiviral treatmentsThis project aims to identify and characterize virus-encoded transmembrane proteins as novel pharmaceutical targets for antiviral drug discovery and treatment of viral infections. | ERC Advanced... | € 2.420.301 | 2023 | Details |
Hit-to-Lead Development of potent broad-spectrum coronavirus fusion inhibitorsThis project aims to develop and optimize broad-spectrum antiviral drugs targeting the S2 domain of coronaviruses to prevent future outbreaks and enhance antiviral therapy markets. | ERC Proof of... | € 150.000 | 2022 | Details |
Broad-spectrum Antiviral siRNAs: Influenza Strains Targeted by AnticipationThe BARISTA project aims to develop a novel antiviral therapy for future influenza strains using optimized siRNA guided by NMR analysis, enhancing preparedness against emerging viruses. | ERC Proof of... | € 150.000 | 2025 | Details |
THERAPRODit project richt zich op het ontwikkelen van een behandeling voor West-Nile- en Chikungunya-virusinfecties door innovatieve screening van stoffen, om de virusvermenigvuldiging te stoppen. | Mkb-innovati... | € 163.275 | 2019 | Details |
Virus Inhibition by siRNA Optimized by NMR
This project aims to develop a novel class of siRNA molecules targeting SARS-CoV-2 variants using structural biology, with potential applications for other pathogenic viruses.
Molecular dissection of viral genomes for future antiviral treatments
This project aims to identify and characterize virus-encoded transmembrane proteins as novel pharmaceutical targets for antiviral drug discovery and treatment of viral infections.
Hit-to-Lead Development of potent broad-spectrum coronavirus fusion inhibitors
This project aims to develop and optimize broad-spectrum antiviral drugs targeting the S2 domain of coronaviruses to prevent future outbreaks and enhance antiviral therapy markets.
Broad-spectrum Antiviral siRNAs: Influenza Strains Targeted by Anticipation
The BARISTA project aims to develop a novel antiviral therapy for future influenza strains using optimized siRNA guided by NMR analysis, enhancing preparedness against emerging viruses.
THERAPRO
Dit project richt zich op het ontwikkelen van een behandeling voor West-Nile- en Chikungunya-virusinfecties door innovatieve screening van stoffen, om de virusvermenigvuldiging te stoppen.